ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES
|
Back to Search Results |
|
Catalog Number 09211101190 |
Device Problems
Incorrect, Inadequate or Imprecise Result or Readings (1535); Output Problem (3005); Non Reproducible Results (4029)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 11/26/2021 |
Event Type
malfunction
|
Manufacturer Narrative
|
A problem report from the liat (b)(4) was provided and found that the alleged sample: on (b)(6) 2021, run (b)(6), scfa lot 11004z, generated sars-cov-2 positive with a ct=36.3, influenza a&b negative.No data for the recollected test result was provided.The late sars-cov-2 ct-value indicates a low viral load sample near the limit of detection (lod) of the assay.Note that samples near or below the lod of the test may generate wavering results upon repeat testing.In addition, sample to sample variability can occur due to: when sample was collected in relation to disease course (pre-symptomatic, or as infection descends to lungs/or patient recovers); how sample was stored prior to testing (sample degradation); or inadequate sample collection.While it is difficult to specify a cross-contamination as a cause.Nonetheless, it is a possibility.Please ensure good lab practices are in place to reduce this chance.Additionally, of note is the unknown collection kit in use.Media with a different chemical composition could contain substances that could interfere with test operation and may impact assay performance.The approved on-label collection kits have been tested and confirmed to be compatible with the scfa assay.Validated collection media kits for each specimen type can be found in the method sheet and are recommended for optimal performance of the assay.Further investigation was performed to rule out a product quality issue.No product problem found.(b)(4).
|
|
Event Description
|
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.A customer alleged a discrepant result with the cobas® sars-cov-2 & influenza a/b nucleic (scfa) acid test for use on the cobas® liat® system.The customer reported that the initial test with the cobas® liat® sn (b)(4), generated sars-cov2 positive, influenza a negative and influenza b negative.A new sample was re-collected and repeated with a different cobas® liat® was negative for all 3 targets.Both positive and negative results were reported to the patient and or/ medical personnel treating the patient.No apparent harm or injury occurred in relation to the event.An investigation was conducted to evaluate the customer¿s allegation.
|
|
Search Alerts/Recalls
|
|
|